BiotechTube

tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lower Urinary Tract Symptoms

Conditions

Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia

Trial Timeline

Apr 26, 2010 → Dec 14, 2011

NCT ID
NCT01021332

About tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)

tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg) is a phase 3 stage product being developed by Astellas Pharma for Lower Urinary Tract Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT01021332. Target conditions include Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01021332Phase 3Completed

Competing Products

20 competing products in Lower Urinary Tract Symptoms

See all competitors
ProductCompanyStageHype Score
JSP191Jasper TherapeuticsPhase 1
25
solifenacin succinate + tamsulosin hydrochloride + Placebo to solifenacin + Placebo to tamsulosinAstellas PharmaPhase 2
52
SolifenacinAstellas PharmaPre-clinical
23
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Vesitirim™ (Solifenacin)Astellas PharmaPre-clinical
23
Mirabegron + PlaceboAstellas PharmaPhase 2
52
tamsulosin hydrochloride + solifenacin succinate + PlaceboAstellas PharmaPhase 2
52
Tamsulosin + SolifenacinAstellas PharmaApproved
85
Tamsulosin OCASAstellas PharmaApproved
85
DuloxetineShionogiPhase 3
77
Duloxetine + PlaceboShionogiPhase 3
77
AZD1656AstraZenecaPhase 1
33
Nirsevimab + PlaceboAstraZenecaPhase 3
77
RSVpreF + PlaceboPfizerPhase 3
76
GabapentinPfizerApproved
84
Erythropoiesis-stimulating agents (ESAs) + Luspatercept + Lenalidomide + Hypomethylating agents (HMAs) + Reb blood cell transfusionBristol Myers SquibbPre-clinical
22
ALX-0171 1.5 mg/kgSanofiPhase 2
51
ALX-0171 3.0 mg/kg + ALX-0171 6.0 mg/kg + ALX-0171 9.0 mg/kgSanofiPhase 2
51
ALX-0171 Dose 1 + ALX-0171 Dose 2 + PlaceboSanofiPhase 2
51
Placebo + Hydrocodone bitartrateUCBPhase 3
74

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85